Published in Gene Therapy Weekly, August 10th, 2006
Study 1: According to recently published research from Greece, genetically engineered Schwann cells show enhanced migratory potential without impairment of their myelinating ability in vitro.
"Schwann cells, the myelin-forming cells of the PNS, are attractive candidates for remyelination therapy as they can remyelinate CNS axons. Yet their integration in CNS tissue appears hampered, at least in part, by their limited motility in the CNS environment," wrote A.A. Lavdas and colleagues, Hellenic Pasteur Institute.
They continued, "As the polysialylated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.